Physician profile
Danielle Walker
NPI 1841684107
$1,069.16
in general payments reported to CMS, 2019-2025
13 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2023: $22.29 · 2024: $519 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $171.46 | 2025 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $139.75 | 2024-2025 | Ozempic, Wegovy |
| Genentech USA, INC. | $124.30 | 2019 | |
| Glaxosmithkline, LLC. | $108.01 | 2024-2025 | Trelegy Ellipta |
| Sun Pharmaceutical Industries INC. | $93.98 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $76.05 | 2024 | |
| Pfizer INC. | $67.04 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $65.99 | 2024-2025 | Breztri, Farxiga |
| Exact Sciences Corporation | $59.74 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $52.10 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $46.11 | 2024-2025 | Repatha, Prolia, Evenity |
| Dexcom, INC. | $41.77 | 2024-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $22.86 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.